We are proposing a binding mechanism to allow people access to medicines and hold Transnational Corporations (TNCs) responsible for violating a human right if they block their access. Intellectual Property Rights (IPR) is one of the pillars of global corporate power, that we are countering with the Global Campaign to Dismantle Corporate Power.
In a historic vote, the United Nations (UN) has finally recognised the medicinal value of cannabis.
A group of prominent drug policy organisations has welcomed the move, but also expressed disappointment that this reform does not go far enough, as cannabis remains categorised internationally alongside drugs like heroin and cocaine.
The review was revisiting cannabis scheduling decisions made in the 1950s, which were driven by prevailing racist and colonial attitudes, and not based on scientific evaluations. This has remained unchallenged.
This week, representatives of around 100 countries are meeting in New York to talk about investor-state dispute settlement (ISDS). ISDS is a legal instrument that multinationals can use to sue governments for billions. External experts and observers fear that the new negotiations will amount to ‘old wine in new bottles’. They believe that those who benefit from this instrument (powerful states and top lawyers from the ISDS sector) are controlling the debate.
With protests, rallies and petitions, the message from the public has been clear: the water service in Jakarta should be re-municipalised, to save the water system from financial ruin and the water service from a profit-oriented private sector.
This is a guide to regulating legal markets for the non-medical use of cannabis. It is for policy makers, drug policy reform advocates and affected communities all over the world, who are witnessing the question change from, 'Should we maintain cannabis prohibition?' to 'How will legal regulation work in practice?
The mayor of Bogota has recently proposed a pilot scheme with crack cocaine addicts to explore the substitution of crack made of cocaine base paste (or bazuco as it is called in Colombia) by marijuana. The substitution treatment plan will include 15 problematic users from the marginalized Bronx area who are already receiving health assistance of the CAMAD operating in that sector of the city. The treatment will last approximately eight months, after which the results will be evaluated.
The ground-breaking new Public-Public Partnership (PUP) between the
Argentinean public water utility Aguas Bonaerenses S.A. (ABSA) and
SEDAM, the provincial water utility of Huancayo (Peru) is an important
example of the growing trend of not-for-profit cooperation between
public utilities from the South.
As an island that is viewed as the mecca of cannabis culture, many are surprised to learn that Jamaica is only now in the midst of reforming its cannabis laws. The cultivation, selling, and consumption of cannabis as all other drugs have been illegal since 1913. However, following a unanimous symbolic vote in the Jamaican House of Representatives last October, the Jamaican government announced in June 2014 that it would decriminalise marijuana possession for personal consumption and religious/medical use by the end of the year. In January 2015, Justice minister Mark Golding introduced a Bill that in addittion to decriminalizing the possession of ganja up to two ounces, it would establish a cannabis licensing authority to regulate cultivation, sale and distribution for medical, scientific and therapeutic purposes. The Bill passed both in Senate and House of Representatives on February 2015.
This debate on Thursday 25 October focusses on the impact of pollution on indigenous peoples as well as the working of national and international legal instruments, in particular The Hague Court of Arbitration. How does it operate? Who are the judges? Who benefits?
Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and prescribe it when appropriate prior to using opioids. This harm reduction strategy may reduce the morbidity and mortality rates associated with prescription pain medications.
Janet E. Joy, Stanley J. Watson, Jun Borras, Sebastian Scholl , John A. Benson, Wendy Wolford
01 January 1999
The medical use of marijuana is surrounded by a cloud of social, political, and religious controversy, which obscures the facts that should be considered in the debate. This book summarizes what we know about marijuana from evidence-based medicine--the harm it may do and the relief it may bring to patients. The book helps the reader understand not only what science has to say about medical marijuana but also the logic behind the scientific conclusions.